AMGEN INC. $500,000,000 6.15% SENIOR NOTES DUE 2018 $500,000,000 6.90% SENIOR NOTES DUE 2038 Underwriting AgreementUnderwriting Agreement • May 23rd, 2008 • Amgen Inc • Biological products, (no disgnostic substances) • New York
Amgen Inc., a Delaware corporation (the “Company”), proposes, subject to the terms and conditions stated herein, to issue and sell to the Underwriters named in Schedule I hereto (the “Underwriters”) an aggregate of $500,000,000 principal amount of the 6.15% Senior Notes due 2018 of the Company (the “2018 Notes”) and an aggregate of $500,000,000 principal amount of the 6.90% Senior Notes due 2038 of the Company (the “2038 Notes” and, together with the 2018 Notes, the “Securities”) to be issued pursuant to the provisions of an Indenture, dated as of August 4, 2003 (the “Indenture”), between the Company and the Bank of New York, as successor to JPMorgan Chase Bank, N.A., as Trustee (the “Trustee”).
